Abstract
Background
Hyperphosphatemia is very common in patients with end-stage renal disease (ESRD). Recently, a new phosphate binder, sevelamer, has become available in the US to treat this condition. The high cost of sevelamer has significantly impacted on third-party payors such as Florida Medicaid. Calcium acetate is a less expensive drug alternative; however, unlike sevelamer, it is associated with the adverse effect of hypercalcemia. There have been few cost analyses performed on either drug. Moreover, few studies have assessed the economic impact of ESRD with hyperphosphatemia.
Objectives
The aims of this study were to: (i) describe the characteristics of ESRD patients with hyperphosphatemia in terms of demographics, comorbidities, and healthcare utilization; (ii) evaluate the primary cost drivers in the treatment of these patients; and (iii) assess the cost of illness associated with treating ESRD patients with hyperphosphatemia.
Methods
This retrospective study extracted data from the Florida Medicaid database. Healthcare costs were assessed from a third-party payor perspective. The patient inclusion criteria were current use of either sevelamer or calcium acetate and continuous eligibility to receive Florida Medicaid services from July 1, 1999 to December 31, 2002 with a run-in period from July 1, 1999 to December 31, 1999 to ensure that patients had been taking either of the two drugs for at least 6 months. The patient exclusion criteria were documented HIV and hemophilia. The specific direct costs included in the study were hospitalization costs, outpatient costs, emergency room costs, and prescription costs (only those for sevelamer and calcium acetate). The price year for the cost analysis was 2002.
Results
A total of 10 058 recipients constituted the study sample, of which 54.0% were male and 46.0% were female. African Americans represented the largest racial group (45.6%), followed by Caucasians (28.6%). The most frequent comorbidities were hypertension, anemia, and congestive heart failure. Healthcare was most often utilized through facility visits (78.1%), followed by pharmacy-related services (17.2%) and then medical services (4.7%). Based on medical claims, the ambulance service contributed the most to healthcare utilization (8.7%), followed by recipient home visits (3.3%) and inpatient visits (2.1%). Facility claims utilization was dominated by dialysis center visits (48.5%), followed by general hospital visits (43.3%) and nursing home visits (7.4%). The major cost driver for 2000–2 was dialysis center visits ($US95 million), followed by general hospital visits ($US92 million), and prescription medication ($US11 million). The cost analysis revealed that ESRD patients with hyperphosphatemia within Florida Medicaid imposed an economic burden (including facility, medical, and prescription claims) of $US228 million for the years 2000–2.
Conclusions
This is the first study to report the economic impact of ESRD with hyperphosphatemia. Given the high economic burden of this population, efforts should be undertaken to enhance preventative measures for hyperphosphatemia as well as the treatment and recovery of these patients.
Similar content being viewed by others
References
National Institute of Diabetes and Digestive and Kidney Diseases. Kidney and urologic diseases statistics for the United States [online]. National Kidney and Urologic Diseases Information Clearinghouse. Available from URL: http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/index.htm [Accessed 2006 Feb 7]
United States Renal Data System. 1999 annual data report [online]. Available from URL: http://www.usrds.org/adr_1999.htm [Accessed 2006 Feb 7]
United States Renal Data System. 2000 annual data report [online]. Available from URL: http://www.usrds.org/adr_2000.htm [Accessed 2006 Feb 7]
Transplant Resource Center of Maryland. Donation information: the kidneys [online]. Available from URL: http://www.mdtransplant.org/default.asp?id=37 [Accessed 2006 Mar 16]
US National Institutes of Health. Morbidity and mortality of dialysis. NIH consensus statement 1993 Nov 1–3; 11(2): 1–33 [online]. Available from URL: http://consensus.nih.gov/1993/1993Dialysis093html.htm [Accessed 2006 Feb 7]
Florida Health Information Center, College of Public Health, University of South Florida. Florida dialysis study final report. Tallahassee (FL): Florida Agency for Health Care Administration, 2000
Florida’s efforts to develop medication formularies within the Medicaid represents wider trend. Mental Health Weekly 2001; 11 (33): 1–5
Justification review: Medicaid disease management initiative sluggish, cost savings not determined, design changes needed [online]. Tallahassee (FL): Florida Legislature Office of Program Policy Analysis and Government Accountability, 2001 May. Report no. 01–27. Available from URL: http://www.oppaga.state.fl.us/reports/pdf/0127rpt.pdf [Accessed 2006 Feb 7]
Justification review: expected Medicaid savings unrealized; performance, cost information not timely for legislative purposes [online]. Tallahassee (FL): Florida Legislature Office of Program Policy Analysis and Government Accountability, 2001 Nov. Report no. 01–61. Available from URL: http://www.oppaga.state.fl.us/reports/health/r01-61s.html [Accessed 2006 Feb 7]
Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607–17
Levin NW, Hulbert-Shearon TE, Strawderman RL, et al. Which causes of death are related to hyperphosphatemia in hemodialysis patients [abstract]. J Am Soc Nephral 1998; 9: 217A
Emmett M, Hootkins R. Phosphorus binders. The Nephrology Exchange 1992; 2: 7–12
Bleyer AJ, Garrett B, Kant KS, et al. An open-label, cross over study of the new phosphate binder Renagel in the management of hyperphosphatemia in ESRD patients. Am J Kidney Dis 1999; 33: 694–701
Mai ML, Emmett M, Sheikh MS, et al. Calcium acetate, an effective phosphorous binder in patients with renal failure. Kidney Int 1989; 36: 690–5
Qunibi WY, Nolan CR. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int Suppl 2004; (90): S33–8
Chertow GM, Dillon M, Burke SK, et al. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium. Clin Nephral 1999; 51: 18–26
Chertow GM, Burke SK, Raggi P, et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245–52
National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease [online]. Available from URL: http://www.kidney.org/professionals/kdoqi/guidelines_bone/ [Accessed 2005 Feb 7]
Shaheen FA, Akeel NM, Badawi LS, et al. Efficacy and safety of sevelamer: comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. Saudi Med J 2004; 25: 785–91
Almirall J, Lopez T, Vallve M, et al. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients. Nephron Clin Pract 2004; 97: c17–22
Collins AJ, Peter WL, Dalleska FW, et al. Hospitalization risks between Renagel phosphate binder treated and non-Renegel treated patients. Clin Nephrol 2000; 54: 334–41
Brophy DF, Wallace JF, Kennedy DT, et al. The cost effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia. Pharmacotherapy 2000; 20(8): 950–7
United States Renal Data System. 2004 annual data report [online]. Available from URL: http://www.usrds.org/adr_2004.htm [accessed 2006 Mar 14]
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332–42
Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost effectiveness analysis. JAMA 2003; 290: 3101–14
Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood) 2001; 20: 11–29
Navarro RP. Managed care pharmacy practice. Gaithersburg (MD): Aspen Publishers Inc., 1999: 397–432
Nolan CR. Strategies for improving long term survival in patients with ESRD. J Am Soc Nephrol 2005; 16 Suppl. 2: S120–7
Huybrechts KF, Care JJ, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005; 5: 549–61
Acknowledgments
The authors would like to thank Dr Abraham Hartzema for reviewing the manuscript and Dr Ed Ross for input on the clinical progression of ESRD and hyperphosphatemia. No sources of funding were used to assist in the preparation of this study. The authors declare no personal, intellectual or other conflicts of interest or financial interests in any company, product, or service mentioned in the article, including grants, employment, gifts, and honoraria.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
White, A., Odedina, F., Xiao, H. et al. The Economic Burden of End-Stage Renal Disease with Hyperphosphatemia. Dis-Manage-Health-Outcomes 14, 99–106 (2006). https://doi.org/10.2165/00115677-200614020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00115677-200614020-00005